4d pharma plc's (LON:DDDD) Duncan Peyton talks to Proactive London following the positive results of its clinical results in the first part of a trial on very poorly patients battling cancer.
The trial of its live biotherapeutic in combination with an established cancer drug called a checkpoint inhibitor resulted in five people, or 42% of the group, experiencing a clinically meaningful benefit from the two drugs.
Peyton explains how this is the first time live biotheroputics have been used in this way and without any side effects.